PALO ALTO, California, May 1, 2026
Sonire Therapeutics Inc. announced the initiation of its first U.S. clinical trial, SUNRISE-II, evaluating its proprietary ultrasound-guided High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of pancreatic cancer. This feasibility study, designed to assess safety and technical performance in approximately 10 patients, marks a critical step in the company’s expansion into the U.S. clinical and regulatory landscape. With pancreatic cancer remaining one of the deadliest malignancies, characterized by a five-year survival rate of around 13%, Sonire’s approach aims to address a significant unmet clinical need through a minimally invasive, anesthesia-free treatment platform.
Advancing Minimally Invasive Cancer Treatment
Sonire’s HIFU system represents a next-generation non-invasive tumor ablation technology that uses focused ultrasound energy to precisely target and destroy cancerous tissue without surgical incisions. The system integrates real-time ultrasound imaging, allowing clinicians to monitor treatment delivery with high precision and adjust parameters instantly. This capability not only enhances treatment accuracy but also reduces collateral damage to surrounding healthy tissues. Unlike conventional surgical or radiation-based interventions, the HIFU platform is designed to operate without general anesthesia, significantly lowering procedural risks and improving patient tolerability. This approach could potentially shift cancer treatment toward outpatient settings, reducing hospital burden and improving accessibility for patients who are not candidates for invasive procedures.
SUNRISE-II Trial Design and Clinical Significance
The SUNRISE-II clinical trial is structured as a first-in-U.S. feasibility study, focusing on validating the safety profile and operational performance of the HIFU system in real-world clinical conditions. The first patient was treated in March 2026 at a leading U.S. institution, signaling early clinical momentum. By targeting pancreatic tumors—known for their complex anatomical location and resistance to standard therapies—the study aims to demonstrate whether image-guided acoustic energy delivery can offer a viable alternative to current treatment modalities. The trial builds upon Sonire’s prior development experience in Japan, where early-stage work has supported the technical feasibility and therapeutic potential of the platform. Positive outcomes from SUNRISE-II could pave the way for larger pivotal trials and regulatory submissions, accelerating the pathway toward commercialization in the U.S. and globally.
Advertisement
Strategic Expansion into U.S. Clinical Development
The launch of SUNRISE-II reflects Sonire’s broader strategy to establish a robust clinical evidence base in high-value markets, particularly the United States. By collaborating with leading medical institutions and investigators, the company aims to generate high-quality clinical data that can support regulatory approvals and physician adoption. The HIFU platform aligns with the growing trend toward precision oncology and non-invasive therapeutic technologies, which prioritize patient safety, reduced recovery times, and improved quality of life. Sonire’s focus on acoustic engineering and real-time imaging integration positions it at the intersection of innovation in both medical devices and cancer therapy delivery systems. If successful, the technology could expand beyond pancreatic cancer into other solid tumor indications, significantly broadening its clinical impact.
The initiation of this trial underscores the increasing importance of device-based cancer therapies as complementary or alternative solutions to traditional drug-based treatments. By combining engineering innovation with clinical need, Sonire Therapeutics is advancing a new paradigm in oncology care—one that emphasizes precision, minimal invasiveness, and scalability. As the SUNRISE-II study progresses, its outcomes will be closely watched by clinicians, regulators, and industry stakeholders seeking transformative solutions for hard-to-treat cancers.
Source: Sonire Therapeutics press release
